United States
Germany
Japan
United Kingdom
China
Rabbit Polyclonal Anti-FASL Antibody
| Applications | WB |
| Reactivities | Human, Mouse |
Products
Fas Ligand (FASLG) (C-term) rabbit polyclonal antibody, Aff - Purified
| Applications | IHC, WB |
| Reactivities | Human, Mouse, Rat |
FASLG HEK293T cell transient overexpression lysate (as WB positive control)
| Tag | C-Myc/DDK |
| Expression Host | HEK293T |
FASLG - human gene knockout kit via CRISPR, HDR mediated
| Format | 2 gRNA vectors, 1 GFP-puro donor, 1 scramble control |
| Donor DNA | GFP-puro |
Rabbit Polyclonal Anti-FAS ligand Antibody
| Applications | WB |
| Reactivities | Human |
FASLG - human gene knockout kit via CRISPR, HDR mediated
| Format | 2 gRNA vectors, 1 Luciferase-Puro donor, 1 scramble control |
| Donor DNA | Luciferase-Puro |
FASLG - human gene knockout kit via CRISPR, HDR mediated
| Format | 2 gRNA vectors, 1 RFP-BSD donor, 1 scramble control |
| Donor DNA | RFP-BSD |
FASLG - human gene knockout kit via CRISPR, HDR mediated
| Format | 2 gRNA vectors, 1 mBFP-Neo donor, 1 scramble control |
| Donor DNA | mBFP-Neo |
FASLG (untagged)-Human Fas ligand (TNF superfamily, member 6) (FASLG)
| Type | Human Untagged Clone |
| Tag | Tag Free |
| Vector | pCMV6-AC |
3' UTR clone of Fas ligand (TNF superfamily member 6) (FASLG) for miRNA target validation
| Vector | pMirTarget |
| Species | Human |
| Transfection Reporter | RFP |
| Assay Reporter | Luciferase |
FASLG (untagged) - Human Fas ligand (TNF superfamily, member 6) (FASLG), transcript variant 2
| Type | Human Untagged Clone |
| Tag | Tag Free |
| Vector | pCMV6-Entry |
Recombinant Human Fas Ligand (N-6His)
| Tag | N-6His |
活动过滤器
优化搜索结果
Species
Antibody Hosts
Expression Hosts
Lentivirus
Vectors
Conjugates
Clonalities
Mutants
Pathways
- Allograft rejection (21)
- Apoptosis (21)
- Autoimmune thyroid disease (21)
- Cytokine-cytokine receptor interaction (21)
- Graft-versus-host disease (21)
- MAPK signaling pathway (21)
- Natural killer cell mediated cytotoxicity (21)
- Neurotrophin signaling pathway (21)
- Pathways in cancer (21)
- Type I diabetes mellitus (21)
